From Yahoo Finance: 2025-05-07 18:58:00

Relay Therapeutics, Inc. (RLAY) is trading at $3.15 and is focused on RLY-2608, a PI3Kα inhibitor for tumors with PIK3CA mutations, showing early efficacy in breast cancer. The company’s strategic shift includes cost control measures, an extended cash runway, and exploring combination therapies. RLAY is not among the 30 most popular stocks among hedge funds.

RLAY is streamlining operations, reducing spending, and focusing on RLY-2608 for pivotal trials. Promising early efficacy data supports its advancement into a Phase 3 trial for breast cancer treatment. RLAY is also pursuing additional indications like PI3K-driven vascular malformations. Combination therapies and upcoming trial results could further validate RLY-2608’s potential in cancer treatment.

While RLAY is not a top choice for hedge funds, its concentrated focus on RLY-2608 and potential combination therapies position it as a high-conviction biotech story. The company’s disciplined financial management, long cash runway, and multiple clinical strategies enhance its risk/reward profile for investors. Hedge funds continue to hold RLAY in their portfolios, but other AI stocks may offer greater promise for higher returns in a shorter timeframe.

Read more: Relay Therapeutics, Inc. (RLAY): A Bull Case Theory